BIAF_OUT_1 [2025-04-01 04:00:41 -0400] 2476 Bytes | 676 tokens | Cum: 676 tkns (8.45% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 4:00:39 AM on Tue Apr 01, 2025 -0400, and I'm firing up the spotlight on bioAffinity Technologies (BIAF), moving from 0.26 to 0.6883. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for bioAffinity Technologies:

C1 - Mar-31-25 09:28AM - bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
C2 - Mar-26-25 09:00AM - Case Study: bioAffinity Technologies CyPath Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
C3 - Mar-19-25 09:00AM - Case Study: bioAffinity Technologies Positive CyPath Lung Result Leads to Detecting Breast Cancer Recurrence
C4 - Mar-13-25 09:00AM - Physicians Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
C5 - Mar-06-25 08:00AM - bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath Lung Sales Growth
C6 - Feb-26-25 12:10PM - WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
C7 - Feb-26-25 12:10PM 11:30AM - bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
C8 - Feb-25-25 11:05AM - WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Prior AI Reports for BIAF:
1. 2025-03-31 – Score: 30 – Target: 0.6683 – Highs: 0.2929 / – / –
high-sales-growth-amid-severe-underperformance-a-paradox-unveiled

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on bioAffinity Technologies (BIAF)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

BIAF_OUT_3 [2025-04-01 04:00:48 -0400] 508 Bytes | 157 tokens | Cum: 835 tkns (10.44% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1): C1:
**bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024**
Date: Mar-31-25 09:28AM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20250331662400/en/

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20250331662400/en/

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BIAF_OUT_5 [2025-04-01 04:00:48 -0400] 983 Bytes | 284 tokens | Cum: 1278 tkns (15.97% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adver...
A2 - 2025-03-31T13:34:26Z - bioAffinity posts 270% revenue rise with Medicare coverage By Investing.com...
A3 - 2025-03-31T13:35:48Z - bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024...
A4 - 2025-03-28T13:14:12Z - bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big M...
A5 - 2025-03-28T13:02:00Z - RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the Re...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BIAF_OUT_7 [2025-04-01 04:00:58 -0400] 1098 Bytes | 337 tokens | Cum: 1617 tkns (20.21% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adverum Biotechnologies (NASDAQ:ADVM)**Date: 2025-03-31Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44573149/12-health-care-stocks-moving-in-mondays-after-market-sessionGainers bioAffinity Technologies BIAF stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. Nutex Health NUTX shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. Compass Therapeutics CMPX stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. Plus Therapeutics PSTV stock moved upwards by 17.7% to $1.13. The market value of their

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BIAF_OUT_9 [2025-04-01 04:00:59 -0400] 1056 Bytes | 319 tokens | Cum: 2100 tkns (26.25% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-03-11T17:41:28Z - Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
B2 - 2024-03-06T19:35:14Z - Nasdaq Gains 100 Points; Campbell Soup Earnings Top Views
B3 - 2024-03-06T18:54:52Z - Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B4 - 2024-03-05T18:11:47Z - Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B5 - 2023-12-19T18:34:55Z - Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B6 - 2023-10-04T16:48:11Z - Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BIAF_OUT_11 [2025-04-01 04:01:06 -0400] 1100 Bytes | 335 tokens | Cum: 2437 tkns (30.46% of 8k)
==========================================================================

Showing B1 (chunk 1 of 3): B1:
**Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/03/37595253/why-mesoblast-shares-are-trading-higher-by-13-here-are-other-stocks-moving-in-mondays-mid-day-sessioShares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients.
Mesoblast shares jumped 13.4% to $2.4399 on Monday.
Here are some other stocks moving in today's mid-day session.
Gainers

Kidpik Corp. (NASDAQ: PIK) gained 238% to $9.15. Kidpik recently announced a 1-for 5 reverse stock split.
TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares surged 149% to $2.6450.
TRxADE HEALTH, Inc. (NASDAQ: MEDS) gained 114.6% to $17.26. TRxADE Health recently

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BIAF_OUT_13 [2025-04-01 04:01:06 -0400] 1105 Bytes | 283 tokens | Cum: 2841 tkns (35.51% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 8-K Item 2.02. Results of Operation and Fin Cond.

On March 31, 2025, bioAffinity Technologies, Inc., a Delaware corporation (the Company), issued a press release that included financial information for its year ended December 31, 2024. A copy of the press release is atta...

S2 - 2025-03-31 8-K Item 2.02. Results of Operation and Fin Cond.

On March 31, 2025, bioAffinity Technologies, Inc., a Delaware corporation (the Company), issued a press release that included financial information for its year ended December 31, 2024. A copy of the press release is atta...

S3 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

This section presents managements perspective on our financial condition and results of operations. The following discussion and analysis (the MDA) is intended to highlight and supple...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BIAF_OUT_15 [2025-04-01 04:01:13 -0400] 1098 Bytes | 290 tokens | Cum: 3133 tkns (39.16% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 2.02. Results of Operation and Financial Condition.

On March 31, 2025, bioAffinity Technologies, Inc., a Delaware corporation (the Company), issued a press release that included financial information for its year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Se

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BIAF_OUT_17 [2025-04-01 04:01:25 -0400] 4697 Bytes | 1373 tokens | Cum: 4641 tkns (58.01% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+--------------------------+------------------------+
| Volume: 24,297,124 | Perf Month: -48.00% | Option/Short: No / No | Sales Y/Y TTM: 269.68% |
+---------------------+-----------------------+--------------------------+------------------------+
| Avg Volume: 264.20K | Perf Quarter: -72.63% | Short Float: 2.55% | ROE: -242.44% |
+---------------------+-----------------------+--------------------------+------------------------+
| Rel Volume: 91.97 | Index: - | Short Ratio: 0.91 | ROI: -265.19% |
+---------------------+-----------------------+--------------------------+------------------------+
| RSI (14): 26.23 | Market Cap: 4.05M | Short Interest: 0.24M | Sales Surprise: -8.93% |
+---------------------+-----------------------+--------------------------+------------------------+
| ATR (14): 0.06 | Shs Outstand: 15.58M | Beta: 3.45 | EPS Surprise: -35.71% |
+---------------------+-----------------------+--------------------------+------------------------+
| SMA20: -18.67% | Shs Float: 9.42M | Sales Q/Q: -0.26% | P/E: - |
+---------------------+-----------------------+--------------------------+------------------------+
| SMA50: -53.80% | Inst Own: 3.44% | Sales past 5Y: 13156.86% | Earnings: Mar 31 BMO |
+---------------------+-----------------------+--------------------------+------------------------+
| SMA200: -81.03% | Insider Own: 39.53% | Employees: - | |
+---------------------+-----------------------+--------------------------+------------------------+
| Perf Week: -9.78% | Insider Trans: 0.00% | Debt/Eq: 0.58 | |
+---------------------+-----------------------+--------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: bioAffinity Technologies, Inc. (BIAF) by Edwards James Michael (VP and CFO) on 2025-01-10
- Common Stock: 6172 shares at $0 (D)

Inside Trans: bioAffinity Technologies, Inc. (BIAF) by Zannes Timothy P (Secretary, EVP, Gen. Counsel) on 2025-01-10
- Common Stock: 8641 shares at $0 (D)

Inside Trans: bioAffinity Technologies, Inc. (BIAF) by GIRGENTI STEVEN (Executive Chairman) on 2025-01-10
- Common Stock: 14814 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 9415243.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 8771245.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.26
Average Volume: 2381508.38
30-Day High: 0.4108
30-Day Low: 0.26

[Detailed Financials: Q3 2024]
- Total Assets: $6,552,014.0
- Total Liabilities: $3,430,989.0
- Total Equity: $3,121,025.0
- Current Assets: $2,549,138.0
- Current Liabilities: $2,491,164.0

[Income Statement: Q3 2024]
- Revenue: $2,350,386.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.16

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-44,731

[Detailed Financials: Q2 2024]
- Total Assets: $6,656,448.0
- Total Liabilities: $3,223,334.0
- Total Equity: $3,433,114.0
- Current Assets: $2,680,431.0
- Current Liabilities: $2,326,288.0

[Income Statement: Q2 2024]
- Revenue: $2,397,652.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.19

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-1,651,854.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

BIAF_OUT_19 [2025-04-01 04:01:27 -0400] 676 Bytes | 167 tokens | Cum: 5104 tkns (63.80% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

BIAF_IN_21 [2025-04-01 04:01:27 -0400] 126 Bytes | 29 tokens | Cum: 5161 tkns (64.51% of 8k)
==========================================================================

====================================
[2025-04-01 04:01:27] # Analysis Completed
Elapsed Time: 47.84 seconds